HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver

References

• World Cancer Research Fund, International. Available from: http://www.wcrf.org. Cited on 15th, June 2014.
   Google Scholar
• Sjovall A, Jarv V, Blomqvist L, Singnomklao T, Cedermark B, Glimelius B, et al. The potential for improved outcome in patients with hepatic metastases from colon cancer: A population-based study. Eur J Surg Oncol 2004;30: 834–41.
   PubMed Web of Science ®Google Scholar
• Maringe C, Walters S, Rachet B, Butler J, Fields T, Finan P, et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: A population-based study of patients diagnosed during 2000–2007. Acta Oncol 2013;52: 919–32.
   PubMed Web of Science ®Google Scholar
• Morris EJ, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010;97:1110–8.
   PubMed Web of Science ®Google Scholar
• Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: Review and meta-analysis of prognostic factors. Clin Epidemiol 2012;4:283–301.
   PubMedGoogle Scholar
• Hamilton SR, Bosman FT, Boffetta P, et al. Carcinoma of the colon and rectum. In: Bosman FT, editor. WHO classification of tumours of the digestive system, 4th ed. Lyon: IARC; 2010. pp. 134–46.
   Google Scholar
• Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007;60:1112–6.
   PubMed Web of Science ®Google Scholar
• Berg M, Søreide K. Genetic and epigenetic traits as biomarkers in colorectal cancer. Int J Mol Sci 2011;12:9426–39.
   PubMed Web of Science ®Google Scholar
• Lee JC, Wang ST, Chow NH, Yang HB. Investigation of the prognostic value of coexpressed ErbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002;38:1065–71.
   PubMed Web of Science ®Google Scholar
• Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998;29:771–7.
   PubMed Web of Science ®Google Scholar
• Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: A meta-analysis. J Natl Cancer Inst 2013;105:266–73.
   PubMedGoogle Scholar
• Desai MD, Saroya BS, Lockhart AC. Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. Expert Opin Investig Drugs 2013; 22:341–56.
   PubMed Web of Science ®Google Scholar
• Hsieh A, Moasser M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007;97:453–7. Review.
   PubMed Web of Science ®Google Scholar
• Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008; 15:413–48.
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Nishikawa Y, Ito R, Kawamata M, Doi Y, Yamamoto Y, et al. Significance of integrin alphavbeta5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. Cancer Sci 2010;101:2011–8.
   PubMed Web of Science ®Google Scholar
• Beji A, Horst D, Engel J, Kirchner T, Ullrich A. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 2012;18:956–68.
   PubMed Web of Science ®Google Scholar
• Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 2010;21:944–50.
   PubMed Web of Science ®Google Scholar
• Campbell MR, Amin D, Moasser MM. HER3 comes of age: New insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010;16:1373–83.
   PubMed Web of Science ®Google Scholar
• Lédel F, Hallström M, Ragnhammar P, Ohrling K, Edler D. HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. Eur J Cancer 2014;50:656–62.
   PubMed Web of Science ®Google Scholar
• Wei Q, Shui Y, Zheng S, Wester K, Nordgren H, Nygren P, et al. EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncol Rep 2011;25:3–11
   PubMed Web of Science ®Google Scholar
• Ljuslinder I, Malmer B, Isaksson-Mettavainio M, Oberg A, Henriksson R, Stenling R, et al.ErbB 1–4 expression alterations in primary colorectal cancers and their corresponding metastases. Anticancer Res 2009;29:1489–94.
   PubMed Web of Science ®Google Scholar
• Peeples C, Shellnut J, Wasvary H, Riggs T, Sacksner J. Predictive factors affecting survival in stage II colorectal cancer: Is lymph node harvesting relevant? Dis Colon Rectum 2010;53:1517–23.
   PubMed Web of Science ®Google Scholar
• Slesser AA, Georgiou P, Brown G, Mudan S, Goldin R, Tekkis P. The tumour biology of synchronous and metachronous colorectal liver metastases: A systematic review. Clin Exp Metastasis 2013;30:457–70.
   PubMed Web of Science ®Google Scholar
• Tan EK, Ooi LL. Colorectal cancer liver metastases – understanding the differences in the management of synchronous and metachronous disease. Ann Acad Med Singapore 2010; 39:719–15.
   PubMed Web of Science ®Google Scholar
• Miglio U, Mezzapelle R, Paganotti A, Allegrini S, Veggiani C, Antona J, et al. Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. Pathol Res Pract 2013;209:233–6.
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Mandolesi A, Giampieri R, Bittoni A, Pierantoni C, Zaniboni A, et al. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist 2011;16:53–60.
   PubMed Web of Science ®Google Scholar
• Li C, Brand TM, Iida M, Huang S, Armstrong EA, van der Kogel A, et al. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov Med 2013;16:79–92.
   PubMed Web of Science ®Google Scholar
• Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, et al. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Mol Cancer 2013;12:134.
   PubMed Web of Science ®Google Scholar
• Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013;23:603–17.
   PubMed Web of Science ®Google Scholar